Safety and efficacy of the first-generation paclitaxel-eluting stents, the first-generation everolimus-eluting stent versus the second-generation everolimus- or zotarolimus-eluting stents in patients with de novo coronary bifurcation lesions

Trial Profile

Safety and efficacy of the first-generation paclitaxel-eluting stents, the first-generation everolimus-eluting stent versus the second-generation everolimus- or zotarolimus-eluting stents in patients with de novo coronary bifurcation lesions

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel (Primary) ; Sirolimus (Primary) ; Zotarolimus (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top